Seasoned Medical Technology Executive to Support Company Through Next Phase of Growth
SAN JOSE, Calif.–(BUSINESS WIRE)— Outset Medical, a leading med tech innovator delivering first-of-its-kind technology into the growing global dialysis market, today announced the appointment of James Hinrichs to its Board of Directors. In addition to his board service, Mr. Hinrichs will serve as Chair of the company’s Audit Committee.
“We are thrilled to have Jim join our Board of Directors,“ said Outset Medical CEO, Leslie Trigg. “With a 30-year track record of both private and public company success, his governance and financial operations experience in high-growth environments will be invaluable to Outset.”
Mr. Hinrichs has held the role of Chief Financial Officer at multiple companies including Alere Inc. until its sale to Abbott Labs, and CareFusion Corporation until its sale to Becton Dickinson. Mr. Hinrichs also currently serves as a director of Orthofix Inc., Integer Holdings, Acutus Medical and Cibus. He holds undergraduate and graduate degrees in business from Carnegie Mellon University.
“Outset is poised for significant growth, and I’m incredibly excited to join their board,” said Mr. Hinrichs. “The expanded commercialization of Tablo will give providers much needed innovation to reduce the cost and complexity of delivering dialysis.”
Dialysis is delivered to more than 550,000 U.S. patients several times per week to remove waste products and excess fluid from patients with kidney failure. Although more than 85 million dialysis treatments take place in the United States each year at an estimated annual cost of ~$75 billion, little meaningful technology or service model innovation has been introduced in decades.
Outset Medical’s Tablo was designed as an enterprise solution to reduce the cost and complexity of dialysis, while improving the experience for patients and providers. With real-time water purification and dialysis fluid production integrated in a single, compact system, Tablo functions like a dialysis clinic on wheels. Requiring just an electrical outlet and tap water to operate, Tablo frees providers from having to rely on expensive clinic infrastructure, enabling on-demand, cost-effective dialysis in a range of use environments. Tablo was designed to look and feel like an intuitive consumer product, keeping end-user simplicity in mind. Wireless data, sensor-based automation, and an animated touchscreen make Tablo easy to learn and use for healthcare professionals and patients alike.
About the Tablo Hemodialysis System
Tablo is an FDA-cleared enterprise solution for dialysis, designed specifically to reduce the cost and complexity of dialysis across all care settings. Requiring only an electrical outlet and tap water to operate, the mobile Tablo system frees patients and providers from the burdensome infrastructure required to operate conventional dialysis machines. The machine’s integrated functionality enables it to serve as a dialysis clinic on wheels and enables providers to standardize to a single platform that can be used across a wide spectrum of care settings. Wireless data, sensor-based automation and an animated touchscreen make the system easy to learn and use. Leading health systems and medical centers across the U.S. have adopted Tablo for hospital and clinic dialysis, and the U.S. Department of Health and Human Services (HHS) awarded a contract for the use of Tablo in communities hit by natural disasters.
About Outset Medical
Outset Medical is dedicated to technology-driven service model innovation aimed at reducing cost and transforming the patient care experience. Outset’s Tablo System is FDA-cleared for use in acute and chronic care settings. In addition to its acute and chronic care commercial expansion, the company has concluded a clinical trial to expand Tablo’s labeled indication to include home use. For more information visit www.outsetmedical.com and follow the company on Twitter at @OutsetMedical.